Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Salvage treatment options following CAR-T failure in DLBCL

Jaromir Tomasik • 17 Apr 2024
EBMT 2024
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Checkpoint inhibitors

Jaromir Tomasik, Medical University of Warsaw, Warsaw, Poland, discusses a meta-analysis comparing salvage treatment options for patients with diffuse large B-cell lymphoma (DLBCL) who have failed CAR-T therapy. The study found that CAR T-cells targeting antigens other than CD19 had the best outcomes. Bispecific antibodies showed higher response rates than checkpoint or kinase inhibitors, offering another salvage option when non-CD19 CAR T-cells are not available. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

10:31
Comparing haploSCT to other donor types in lymphoma treatment
Ali Bazarbachi • 3 May 2024
2:18
Treating patients with advanced-stage HL in the frontline and relapsed settings in 2024
Graham Collins • 29 Apr 2024
6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals